The size of Intravenous Immunoglobulin (IVIG) market globally reached USD 11.23 Billion in 2021, and it is projected to experience a revenue compound annual growth rate (CAGR) of 6.9% during the forecast period. Factors such as the increasing prevalence of immunodeficiency diseases, advancements in technology, investments in the field, growing adoption of immunoglobulin therapies, and a rising geriatric population are expected to drive the growth of market revenue in the forecast period. IVIG refers to a sterile solution of concentrated antibodies derived from healthy individuals that is administered directly into the vein. It is used for treating immune system disorders or enhancing the immune response.

According to the World Health Organization, by the year 2030, approximately one in six people worldwide will be aged 60 years or older. The proportion of the population aged 60 years and above is projected to increase from 1 billion in 2020 to 1.40 billion. This aging population is susceptible to various health issues due to the accumulation of molecular and cellular damage over time, often resulting in complex health conditions known as geriatric syndromes. The growth of the geriatric population, coupled with the rising prevalence of immunodeficiency disorders and diseases, presents significant concerns for the healthcare ecosystem. Consequently, the increasing geriatric population and the prevalence of immunodeficiency disorders will drive market growth during the forecast period.

Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/1442

Competitive Landscape:

The intravenous immunoglobulin market is moderately fragmented with key players operating on global levels, as sizeable investments in research and development and a robust distributional channel are required to operate in this market. Some key players in the global market report include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd, Shanghai RAAS Blood Products Co., Ltd, CSL Behring LLC, ADMA Biologics, Inc., Baxalta Inc., Biotest AG, Kedrion Biopharma, Inc., China Biologic Products Holdings, Inc., Octapharma AG, Grifols S.A., Pfizer Inc., and LFB Biomedicaments SA.

To know more about the report @ https://www.reportsanddata.com/report-detail/intravenous-immunoglobulin-market

The Intravenous Immunoglobulin (IVIG) Market is influenced by several driving factors and restraints:

Driving Factors:

1. Increasing prevalence of immunodeficiency diseases: The rising incidence of immunodeficiency diseases, such as primary immunodeficiency disorders, autoimmune diseases, and infectious diseases, is a significant driver for the IVIG market. IVIG therapy is used to boost the immune response and treat these conditions, leading to increased demand for IVIG products.
2. Technological advancements and investments: Ongoing advancements in the manufacturing processes, purification techniques, and formulation of IVIG products contribute to improved product quality, efficacy, and safety. Furthermore, increased investments in research and development activities aimed at enhancing IVIG therapies propel market growth.
3. Growing adoption of immunoglobulin therapies: IVIG therapies are increasingly being adopted as a standard treatment option for various immunodeficiency disorders. The expanding awareness among healthcare professionals and patients about the benefits of IVIG, along with its proven efficacy, drives the demand for IVIG products.
4. Growing geriatric population: The aging population is more susceptible to immunodeficiency disorders, autoimmune diseases, and infections, which require IVIG treatment. With a significant increase in the geriatric population globally, the demand for IVIG products is expected to rise.

Restraints:

1. High cost of IVIG therapy: IVIG therapies are often expensive due to the complex manufacturing process and high production costs. The high cost of IVIG products can limit accessibility, particularly in regions with limited healthcare resources or in healthcare systems with budget constraints.
2. Supply-demand imbalances: The demand for IVIG products has been increasing rapidly, leading to occasional supply shortages. The limited availability of IVIG products can create challenges in meeting the growing demand, impacting the market growth.
3. Adverse reactions and side effects: Although IVIG therapy is generally considered safe, some individuals may experience adverse reactions or side effects, such as allergic reactions, infusion-related complications, or blood clotting disorders. These factors can impact patient adherence and contribute to the cautious use of IVIG products.
4. Regulatory challenges: The IVIG market is subject to strict regulatory requirements for product quality, safety, and efficacy. Compliance with these regulations, including obtaining necessary approvals and licenses, can be challenging and time-consuming, affecting market growth.

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1442

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W
Head of Business Development
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Reports and Data | Web: www.reportsanddata.com
Check our upcoming research reports @ https://www.reportsanddata.com/upcoming-reports
Visit our blog for more industry updates @ https://www.reportsanddata.com/blogs